Exciting Presentations on Aligos Therapeutics' Innovations
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a pioneering clinical-stage biopharmaceutical company, recently announced that four of its abstracts have been accepted for presentation at the prestigious American Association for the Study of Liver Disease’s (AASLD) upcoming The Liver Meeting (TLM) 2024. This event will take place from November 15 to 19, 2024, in San Diego. The significance of this opportunity cannot be underestimated as it allows the company to showcase its advancements in therapies targeting liver and viral diseases.
Abstract Highlights from The Liver Meeting
Among the accepted submissions, one is a late-breaker oral presentation, while three others will be poster presentations. This broad representation of data emphasizes Aligos’s commitment to advancing medical knowledge and improving patient outcomes.
ALG-000184: A Potential Game Changer in Treating Chronic Hepatitis B (CHB)
Understanding chronic hepatitis B is crucial, as it affects millions worldwide. Aligos’s study on ALG-000184 highlights its potential as a first- or best-in-class small molecule designed to facilitate capsid assembly modulation. One notable presentation will focus on monotherapy with ALG-000184, showcasing its effectiveness in achieving high viral suppression rates among untreated HBeAg-positive and HBeAg-negative subjects. This presentation, led by Professor Man-Fung Yuen from the University of Hong Kong, could redefine how chronic hepatitis B is treated.
Details of ALG-000184 Presentation
Abstract #: 1213
Title: Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection
Presenter: Professor Man-Fung Yuen
Date/Time: November 15, 2024, 8:00am – 5:00pm PT
Examining the Effectiveness of ALG-055009
In addition to ALG-000184, Aligos Therapeutics will also present data on ALG-055009, a promising treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The oral presentation on this small molecule thyroid hormone receptor beta (THR-?) agonist will address important findings regarding its tolerability and effectiveness in reducing liver fat in patients. This data is crucial for those searching for new treatment options for MASH, a condition that currently has few effective therapies.
Details of ALG-055009 Presentation
Format: Oral presentation
Title: ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-?) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
Presenter: Rohit Loomba, MD
Date/Time: November 19, 2024 at 10:30am – 10:40am PT
About Aligos Therapeutics
Founded with the mission of reshaping patient outcomes, Aligos Therapeutics applies a science-driven approach and extensive research and development expertise. Their pipeline specifically targets high unmet medical needs in liver and viral health, particularly focusing on MASH and hepatitis B. This dedication to advancing healthcare through innovative solutions positions Aligos as a leader in biopharmaceutical development.
Investor and Media Relations
For further inquiries about Aligos Therapeutics, you can reach out to Jordyn Tarazi, Vice President of Investor Relations & Corporate Communications, at +1 (650) 910-0427 or via email. Additionally, media inquiries can be directed to Jake Robison, Vice President at Inizio Evoke.
Frequently Asked Questions
What presentations will Aligos Therapeutics deliver at TLM 2024?
Aligos Therapeutics will present four abstracts, including one late-breaker oral presentation focusing on ALG-055009 and three poster presentations highlighting ALG-000184.
What is ALG-000184?
ALG-000184 is a small molecule designed to target capsid assembly modulation for the treatment of chronic hepatitis B, providing significant viral suppression rates.
Who is presenting the information on ALG-000184?
Professor Man-Fung Yuen from the University of Hong Kong will present the findings related to ALG-000184.
What is MASH, and how does ALG-055009 help?
MASH, or Metabolic Dysfunction-Associated Steatohepatitis, is a liver condition. ALG-055009 is a thyroid hormone receptor beta agonist that shows promise in reducing liver fat.
Who can I contact for more information about Aligos Therapeutics?
For investor inquiries, contact Jordyn Tarazi at +1 (650) 910-0427, and for media inquiries, reach out to Jake Robison.
